Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 3
2016 1
2017 2
2018 2
2019 4
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies.
Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Beaulieu ME, Seras-Franzoso J, Sánchez-García L, Baltà-Foix R, Mancilla S, Fernández Y, Rinas U, Schwartz S Jr, Soucek L, Villaverde A, Abasolo I, Vázquez E. Pesarrodona M, et al. Adv Sci (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/advs.201900849. eCollection 2019 Sep 18. Adv Sci (Weinh). 2019. PMID: 31559131 Free PMC article.
Finding MYCure.
Beaulieu ME, Soucek L. Beaulieu ME, et al. Mol Cell Oncol. 2019 Jun 20;6(5):e1618178. doi: 10.1080/23723556.2019.1618178. eCollection 2019. Mol Cell Oncol. 2019. PMID: 31528695 Free PMC article.
Editorial overview: Peptides in cancer.
Whitfield J, Soucek L. Whitfield J, et al. Curr Opin Pharmacol. 2019 Aug;47:iii-v. doi: 10.1016/j.coph.2019.06.001. Epub 2019 Jun 28. Curr Opin Pharmacol. 2019. PMID: 31257021 Free PMC article. No abstract available.
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L. Beaulieu ME, et al. Sci Transl Med. 2019 Mar 20;11(484):eaar5012. doi: 10.1126/scitranslmed.aar5012. Sci Transl Med. 2019. PMID: 30894502 Free PMC article.
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.
Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L. Jauset T, et al. Oncotarget. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721157 Free PMC article.
Myc and Ras, the Bonnie and Clyde of immune evasion.
Casacuberta-Serra S, Soucek L. Casacuberta-Serra S, et al. Transl Cancer Res. 2018 Apr;7(Suppl 4):S457-S459. doi: 10.21037/tcr.2018.03.09. Transl Cancer Res. 2018. PMID: 31579305 Free PMC article. No abstract available.
Drugging the 'undruggable' cancer targets.
Dang CV, Reddy EP, Shokat KM, Soucek L. Dang CV, et al. Nat Rev Cancer. 2017 Aug;17(8):502-508. doi: 10.1038/nrc.2017.36. Epub 2017 Jun 23. Nat Rev Cancer. 2017. PMID: 28643779 Free PMC article. Review.
Strategies to Inhibit Myc and Their Clinical Applicability.
Whitfield JR, Beaulieu ME, Soucek L. Whitfield JR, et al. Front Cell Dev Biol. 2017 Feb 23;5:10. doi: 10.3389/fcell.2017.00010. eCollection 2017. Front Cell Dev Biol. 2017. PMID: 28280720 Free PMC article. Review.
14 results